New Jersey Headlines

Alzheimer’s Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – BioVie, AB Science, Cassava Sciences, Eli Lilly, TauRx Therapeutics

Alzheimer’s Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – BioVie, AB Science, Cassava Sciences, Eli Lilly, TauRx Therapeutics

September 26
22:20 2023
Alzheimer's Disease  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - BioVie, AB Science, Cassava Sciences, Eli Lilly, TauRx Therapeutics
DelveInsight Business Research LLP
DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the Alzheimer’s disease historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the Alzheimer’s disease historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Alzheimer’s Disease  Key Highlights 

  • Key Companies working in the Alzheimer’s Disease  market include BioVie, AB ScienceCassava Sciences, Eli Lilly, TauRx Therapeutics, Novo Nordisk, KeifeRx, and many others.

  • Key Therapies included in the Alzheimer’s Disease  market include NE3107, PTI-125, ANAVEX2-73 (blarcamesine) and many others 

  • The market size for Alzheimer’s Disease market is USD 3,460.6 million in 2022

Alzheimer’s Disease Overview

Alzheimer’s Disease is a rare, X-linked recessive form of hereditary retinal degeneration that affects roughly 1 in 50,000 males. The disease causes a gradual loss of vision, starting with childhood night blindness, followed by peripheral vision loss and progressing to loss of central vision later in life. Progression continues throughout the individual’s life, but both the rate of change and the degree of visual loss are variable among those affected, even within the same family.

Alzheimer’s Disease is caused by a loss-of-function mutation in the CHM gene which encodes Rab escort protein 1 (REP1), a protein involved in the lipid modification of Rab proteins. While the complete mechanism of disease is not fully understood, the lack of a functional protein in the retina results in cell death and the gradual deterioration of the retinal pigment epithelium (RPE), photoreceptors, and the choroid.

Alzheimer’s Disease  Epidemiology Insights

  • Alzheimer’s Disease is a rare chorioretinal dystrophy that is estimated to affect between 1 in 50,000 to 1 in 100,000 individuals.

Click here to learn more about the Alzheimer’s Disease Market Landscape

The Report Covers the Alzheimer’s Disease  Epidemiology Segmented by:

  • Alzheimer’s Disease  prevalent cases 

  • Alzheimer’s Disease  incident cases 

  • Alzheimer’s Disease  treatment cases 

  • Alzheimer’s Disease  diagnosed cases 

Alzheimer’s Disease  Market Outlook 

The Alzheimer’s Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Alzheimer’s Disease market trends by analyzing the impact of current Alzheimer’s Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Alzheimer’s Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alzheimer’s Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Alzheimer’s Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Companies Working in the Alzheimer Disease  Market 

  • Jazz Pharmaceuticals

  • Otsuka Pharmaceuticals

  • Bionomics Limited

And many others 

 

Alzheimer’s Disease  Therapies Covered and Analyzed in the Report

  • Brexpiprazole 

  • BNC201

And many others 

 

Learn more about the Key Companies and Emerging Therapies in the Alzheimers Disease  Market

Table of Contents 

  1.  Key Insights 

  2.  Alzheimer’s Disease  Introduction 

  3.  Executive Summary of Alzheimer’s Disease          

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  Alzheimer’s Disease  Emerging Therapies

  7.  Alzheimer’s Disease  Market Outlook

  8.  Market Access and Reimbursement of Therapies

  9.  Market Drivers 

  10.  Market Barriers 

  11.  Appendix

  12.  Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

Learn about the detailed offerings of the report @ Alzheimers Disease Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Categories